A result is not the last page
October 2026 · Diabetes results and an unstarted study
What is known now, and which pages are still blank?
Subject One finds a new chapter already bound into the book. Every page is blank. “Printing error?” Doctide taps the date on the study plan. The visitor writes a bookmark: return when there are results.
What changes here
The diabetes population has its own phase 3 result. A newly listed study has a plan, not an outcome. [1]
Read the study details & dates
752 adults with type 2 diabetes and BMI ≥27
At 76 weeks, treatment-regimen weight changes were −8.2% (95% CI −9.2 to −7.2), −9.8% (−10.8 to −8.8) and −3.9% (−4.9 to −2.9) for weekly subcutaneous survodutide 3.6 mg, 6.0 mg and placebo. This estimand incorporates interruption/discontinuation and other specified events. It must not be mixed with on-treatment estimates or the separate trial without diabetes. [1] [2]
SYNCHRONIZE-START: not yet recruiting
This open-label, nonrandomized phase 3 study plans approximately 350 adults without diabetes, in initiation and switching cohorts receiving survodutide; there is no placebo arm. Estimated start: November 7, 2026. Estimated primary completion: November 6, 2029. No results are posted. These are dated registry plans, not an invitation or promise of participation. [3]
What this does not establish
SYNCHRONIZE-2 was sponsor-funded. An abstract is not a full safety dossier. Survodutide remains described as investigational in the reviewed program; a registry listing is not regulatory approval. These chapters cover selected milestones, not every study.
Original sources
- SYNCHRONIZE-2 — primary NEJM abstract, online October 1, 2026
- ClinicalTrials.gov — NCT06066528
- ClinicalTrials.gov — NCT07855900
Primary SYNCHRONIZE-2 abstract and live ClinicalTrials.gov API records reviewed October 27, 2026. Registry status and dates are snapshots; no unpublished outcomes invented.
Journal update record
2026-10-27 · Opened six linked chapters using primary laboratory, animal and clinical sources. Included published phase 3 findings, explicit serious harms and dated SYNCHRONIZE-START status; fictional guide scenes remain separate from evidence.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story